하이로닉 인터내셔널 웹사이트로 이동합니다.
인터내셔널 웹사이트에는 수출용 제품으로 대한민국에서 허가하지 않은 장비 및 서비스 내용을 포함하고 있습니다. 해당 내용은 대한민국의 의료기기 광고 심의, 규제를 받지 않습니다.
It goes to the HIRONIC INTL. website.
The Intrrnation Web Site contains equipment and services that are not authorized by the Republic of Korea These contents are not subject to review and regulation of medical devices in Korea.
하이로닉 US 웹사이트로 이동합니다.
US 웹사이트의 내용은 "FDA"로 부터 허가승인된 품목의 제품 정보에 관한 것으로, 대한민국의 소비자 보호를 위한 국내법 의료기기의 광고 심의, 규제를 받지 않습니다.
It goes to the HIRONIC US website.
The contents of the US web page are about product information of items approved for "FDA". They are not subject to advertising deliberation and regulation of domestic law medical devices for consumer protection in Korea.
하이로닉 EU 웹사이트로 이동합니다.
EU 웹사이트의 내용은 "CE MDD 또는 CE MDR"로 부터 허가승인된 품목의 제품 정보에 관한 것으로, 대한민국의 소비자 보호를 위한 국내법 의료기기의 광고 심의, 규제를 받지 않습니다.
It goes to the HIRONIC EU website.
The contents of the EU(European) web page are about product information of items approved for "CEMDD or CEMDR" in EU countries. They are not subject to advertising deliberation and regulation of domestic law medical devices for consumer protection in Korea.
HIRONIC Co., Ltd has successfully concluded its
participation in the world-renowned aesthetic medical device exhibition, IMCAS 2025, held in Paris, France, from January 30 to
February 2. During the event, HIRONIC showcased its latest technological
advancements, receiving significant attention from industry professionals as it
aggressively pursued global market expansion with its flagship and new
products.
IMCAS is an international platform that annually introduces innovative aesthetic medical devices. At this prestigious venue, HIRONIC unveiled the New DOUBLO 2.0, SILKRO, and its latest device, SYNERJET. The SYNERJET, in particular, garnered significant interest from global distributors and medical professionals as a next-generation device based on needle-free injection technology. It enables faster and more efficient treatments compared to conventional injection therapies. Currently, exclusive distribution agreements are under negotiation in key markets such as the United States and Russia, signaling rapid global market expansion.
The New DOUBLO 2.0, incorporating a fusion of Microfocused Ultrasound (MFU) and Radiofrequency (RF) technologies, demonstrated superior clinical efficacy over existing treatment methods and has secured certifications in multiple countries, including Thailand and Brazil. During a live demonstration session at IMCAS, Dr. Thitikom Lim from Thailand shared insights into the Triple Firm Protocol utilizing the New DOUBLO 2.0, drawing keen interest from attendees.
Meanwhile, SILKRO, an RF microneedling device, also received high praise in the growing global Energy-Based Device (EBD) market. The steady increase in interest in SILKRO during the exhibition further underscores HIRONIC’s expanding global influence.
Additionally, during the exhibition, HIRONIC hosted the ‘Global VVIP Partner Meeting’ to strengthen its collaborative network. Key partners from various countries, including Brazil and Thailand, attended to discuss strategic cooperation, with some being recognized as Top Partners of the Year for their outstanding contributions.
A company representative stated, “IMCAS 2025 was an opportunity to
confirm that our innovative technologies and products are highly competitive on
the global stage.” They further emphasized, “With the exceptionally positive response to SYNERJET, we are highly
optimistic about expanding into new markets and increasing sales.”
